DistantNews
Support us
Beyond Medical X-rays to Industry and Space... Remedy: "Leaping forward as an AI X-ray platform company"
๐Ÿ‡ฐ๐Ÿ‡ท South Korea /Technology

Beyond Medical X-rays to Industry and Space... Remedy: "Leaping forward as an AI X-ray platform company"

From Chosun Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • Remedy, a portable X-ray equipment company, aims to become a global AI-based X-ray platform provider.
  • The company plans to expand its medical, industrial, and core component businesses following its KOSDAQ listing.
  • CEO Cho Bong-ho outlined the growth strategy at a press conference.

Portable X-ray equipment firm Remedy is charting an ambitious course to become a global leader in AI-powered X-ray platforms. Leveraging its upcoming KOSDAQ listing, the company intends to aggressively expand its reach into international markets.

Remedy's strategic vision encompasses broadening its existing medical portable X-ray business, alongside significant growth in industrial non-destructive testing (NDT) and its core component manufacturing operations. This multi-faceted approach aims to establish the company as a comprehensive solutions provider.

At a press conference held at the Fairmont Ambassador Hotel in Seoul, CEO Cho Bong-ho detailed the company's growth strategy. The plan centers on transforming Remedy into an AI-driven X-ray platform enterprise, integrating artificial intelligence to enhance its product offerings and services across various sectors.

The company's focus extends beyond medical applications, targeting industrial inspection needs and strengthening its position in the supply chain for critical X-ray components. This expansion is poised to solidify Remedy's market presence and drive future innovation in X-ray technology.

DistantNews Editorial

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.